ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 56

Prevalence of Serum 14-3-3η in Juvenile Idiopathic Arthritis

Iris Reyhan1, Olga S. Zhukov2, Robert J. Lagier3, Robert Bridgforth4, Gary J Williams5, Joanna M. Popov2, Stanley J. Naides2 and Andreas Reiff6, 1Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, 2Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, 3Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, 4quest diagnostics Nichols Institue, clemente, CA, 5Nicolas Institue, Quest Diagnostics, San Juan Capistrano, CA, 6Children’s Hospital of Los Angeles, Los Angeles, CA

Meeting: 2017 Pediatric Rheumatology Symposium

Keywords: Biomarkers and juvenile idiopathic arthritis (JIA), Diagnostic Tests

  • Tweet
  • Email
  • Print
Session Information

Date: Thursday, May 18, 2017

Session Title: Clinical and Therapeutic Poster Session

Session Type: Abstract Submissions

Session Time: 5:30PM-7:00PM

Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease. Currently, diagnosis is based on clinical assessment defined by the International League of Associations for Rheumatology criteria. Disease specific laboratory biomarkers are limited to rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) antibodies, which are associated with a poor JIA prognosis. The biomarker 14-3-3η (eta) is highly sensitive and specific for rheumatoid arthritis (RA) in adults. Elevated serum 14-3-3η levels improve the diagnostic sensitivity of RF and CCP in adult RA and 14-3-3η level is associated with a more severe RA phenotype [1,2]. The objective of this study was to evaluate the prevalence and clinical significance of serum 14-3-3η in children with JIA.

Methods: One hundred patients from the Pediatric Rheumatology Core at Children’s Hospital of Los Angeles were divided into four groups: 31 with polyarticular JIA RF+ (PJIA RF+), 32 PJIA RF-, 25 oligoarticular JIA (OJIA), and 12 with psoriatic arthritis (PsA). OJIA patients served as a control group. RF, CCP, and 14-3-3η were measured via immunoturbidimetry, immunoassay, and ELISA, respectively. Based on adult onset RA, a 14-3-3η serum level of >0.2ng/mL was considered positive. Association of PJIA with 14-3-3η positivity was performed by Fisher’s exact test. Disease activity was assessed by Juvenile Arthritis Disease Activity Score-71 (JADAS-71), and correlation of 14-3-3η positivity with disease activity and with RF/CCP positivity by the Mantel-Haenszel statistics.

Results: RF, CCP, and 14-3-3η data are summarized in Table 1. Twenty eight patients had a positive 14-3-3η. Eight were single positive for 14-3-3η, 20 were positive for 14-3-3η and RF or CCP, and 15 were positive for all 3 markers. There was positive correlation between 14-3-3η and RF and CCP positivities (p=0.00001), but there was no correlation between presence and titer of 14-3-3η compared to JADAS-71 or age of onset.

Conclusion: All patient groups tested had levels of 14-3-3η above baseline. PJIA RF+ patients had the highest prevalence of 14-3-3η compared to all other groups. There was positive correlation between 14-3-3η and positive RF and CCP, but none with disease activity. Of note, 14-3-3η was positive in other forms of JIA, including OJIA where 25% of patients were positive. 14-3-3η may be a useful biomarker in diagnosis, prognosis and monitoring therapeutic response of children with PJIA RF+. However, its role in other forms of JIA remains to be determined.

References:

1. Maksymowych WP, Marotta A. 14-3-3η: a novel biomarker platform for rheumatoid arthritis. Clin Exp Rheumatol. 2014:32(suppl):S-35-9.

2. Maksymowych WP, Naides SJ, Bykerk V, et al. Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol. 2014;41:2104-2113.

Table 1: Prevalence of 14-3-3η, RF and CCP Across Patient Groups

 

14-3-3η

Positive

Odds Ratio

p-value

14-3-3η

Positive

RF and CCP Negative

14-3-3η

Positive

RF or CCP Positive

14-3-3η

Positive

RF and CCP Positive

PJIA

20/63

(32%)

1.2

0.80

1/63

(2%)

19/63

(30%)

15/63

(24%)

PJIA RF+

18/31

(58%)

3.5

0.03

-0-

18/31

(58%)

15/31

(48%)

PJIA RF-

2/32

(6%)

0.18

0.03

1/32

(3%)

1/32

(3%)

-0-

OJIA

7/25

(28%)

-NA-

-NA-

6/25

(24%)

1/25

(4%)

-0-

PsA

1/12

(8%)

-NA-

-NA-

1/12

(8%)

-0-

-0-

Total

28/100

(28%)

-NA-

-NA-

8/100

(8%)

20/100

(20%)

15/100

(15%)


Disclosure: I. Reyhan, None; O. S. Zhukov, 3; R. J. Lagier, 3; R. Bridgforth, 3; G. J. Williams, 3; J. M. Popov, 3; S. J. Naides, 3,1; A. Reiff, None.

To cite this abstract in AMA style:

Reyhan I, Zhukov OS, Lagier RJ, Bridgforth R, Williams GJ, Popov JM, Naides SJ, Reiff A. Prevalence of Serum 14-3-3η in Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). https://acrabstracts.org/abstract/prevalence-of-serum-14-3-3%ce%b7-in-juvenile-idiopathic-arthritis/. Accessed January 28, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-serum-14-3-3%ce%b7-in-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences